


TEXTBOOK OF DRUG DESIGN AND DISCOVERY

THIRD EDITION



EDITED BY
POVL KROGSGAARD-LARSEN
TOMMY LILJEFORS AND
ULF MADSEN

Contents

List of contributors

xiv

Preface

xvii

1	Drug design and discovery: an overview	1
	LESTER A. MITSCHER	
1.1	Introduction	1
1.2	Historical perspective	2
1.3	What kinds of compounds become drugs?	7
1.4	Preparation and organization for drug seeking	8
1.5	Sources of hits, leads and candidate drugs	11
1.5.1	Natural products	11
1.6	Lead optimization	26
1.7	Cell biology and genomics as a source of drug targets	31
1.8	Future developments	32
	Further reading	33
	References	34
2	Role of molecular recognition in drug design	35
	PETER ANDREWS AND MICHAEL DOOLEY	
2.1	Introduction	35
2.2	Thermodynamic considerations of drug binding	35
2.3	The physical basis of intermolecular interactions	37
2.3.1	Enthalpic contributions	37
2.3.2	Entropic contributions	41
2.4	The total energy of intermolecular interaction	42
2.4.1	Free energy perturbation	42
2.4.2	Partitioning methods	42
2.5	Estimating individual group components in ligand–receptor interactions and co-operativity	43
2.5.1	Intrinsic binding energies	43
2.5.2	Active site mutagenesis	46
2.5.3	‘Average’ functional group contributions	46
2.5.4	The role of ΔG_{t+r}	47

2.6	<i>Some rules of thumb</i>	49
2.6.1	<i>What should this functional group do for my ligand?</i>	49
2.6.2	<i>How well does my ligand fit the receptor?</i>	50
2.6.3	<i>Conclusion</i>	51
	<i>References and further reading</i>	52
3	Stereochemistry in drug design	54
	IAN J. KENNEDY AND DAVID E. JANE	
3.1	<i>Introduction</i>	54
3.2	<i>What are stereoisomers?</i>	55
3.3	<i>The origin of stereospecificity in molecular recognition</i>	59
3.4	<i>Why is stereochemistry important in drug design?</i>	61
3.4.1	<i>The distomer is inactive (high eudismic ratio)</i>	63
3.4.2	<i>Both enantiomers have independent therapeutic benefits</i>	64
3.4.3	<i>Distomer possesses harmful effects</i>	65
3.4.4	<i>The eutomer and the distomer have the opposite biological activity</i>	65
3.4.5	<i>The racemate has a therapeutic advantage over the individual enantiomers</i>	66
3.4.6	<i>One enantiomer converted into the other in the body</i>	67
3.5	<i>Methods of obtaining pure stereoisomers</i>	67
3.5.1	<i>Resolution of racemates by crystallization of diastereomers</i>	68
3.5.2	<i>Enantioselective chromatography</i>	70
3.5.3	<i>Asymmetric synthesis</i>	74
3.6	<i>Analytical methods of determining purity of stereoisomers</i>	81
3.6.1	<i>Optical rotation</i>	81
3.6.2	<i>NMR spectroscopy</i>	82
3.6.3	<i>Gas chromatography</i>	83
3.6.4	<i>Capillary electrophoresis (CE)</i>	83
3.6.5	<i>Mass spectrometry</i>	84
	<i>Further reading</i>	85
4	Computer-aided development and use of three-dimensional pharmacophore models	86
	TOMMY LILJEFORS AND INGRID PETTERSSON	
4.1	<i>Structure- and pharmacophore-based ligand design</i>	86
4.2	<i>The pharmacophore concept</i>	87
4.3	<i>Basic principles and a step-by-step procedure</i>	88
4.4	<i>Pharmacophore elements and their representations</i>	89
4.4.1	<i>Representation of pharmacophore elements as ligand points and site points</i>	90
4.4.2	<i>Comparison of site-points with experimentally observed ligand-protein interactions</i>	92
4.4.3	<i>Representation of pharmacophore elements by explicit molecular properties</i>	93

4.5	<i>The receptor-bound or 'active' conformation</i>	95
4.5.1	<i>Thermodynamic considerations</i>	95
4.5.2	<i>The conformational energy of the bioactive conformation</i>	97
4.5.3	<i>Conformational analysis</i>	99
4.6	<i>Molecular superimposition</i>	102
4.6.1	<i>Least-squares superimposition, flexible fitting and template forcing</i>	102
4.6.2	<i>The use of molecular superimposition techniques</i>	103
4.7	<i>Receptor-excluded and receptor-essential volumes</i>	103
4.8	<i>Solvation effects</i>	104
4.9	<i>Examples of 3D-pharmacophore models and their use</i>	106
4.9.1	<i>Apomorphine congeners: conformational energies vs. agonist activities</i>	106
4.9.2	<i>A 3D-pharmacophore model for dopamine D₂ receptor antagonists</i>	108
4.9.3	<i>3D-pharmacophore models for the design of selective 5-HT_{2A} vs. D₂ receptor antagonists</i>	110
4.9.4	<i>A pharmacophore based database searching for new antimalarial drugs</i>	113
	<i>References</i>	115
	<i>Further reading</i>	115

5 Quantitative structure–activity relationships and experimental design

117

ULF NORINDER AND THOMAS HÖGBERG

5.1	<i>Introduction</i>	117
5.2	<i>Hansch analysis</i>	117
5.2.1	<i>Hydrophobic correlations</i>	117
5.2.2	<i>Multifactorial correlations</i>	118
5.3	<i>Physico-chemical properties</i>	120
5.3.1	<i>Electronic descriptors</i>	120
5.3.2	<i>Hydrophobic parameters</i>	120
5.3.3	<i>Steric descriptors</i>	122
5.3.4	<i>Biological relevance</i>	125
5.4	<i>Applications of Hansch equations</i>	125
5.4.1	<i>Hydrophobic and steric factors</i>	125
5.4.2	<i>Influence of electronic and other factors</i>	126
5.4.3	<i>Ionization constants</i>	128
5.4.4	<i>Predictions from equations</i>	128
5.4.5	<i>Blood–brain barrier penetration</i>	130
5.4.6	<i>Relations to molecular modeling</i>	130
5.5	<i>Pattern recognition</i>	131
5.5.1	<i>PCR and PLS methods</i>	131
5.5.2	<i>Application of PLS</i>	134
5.6	<i>3D-QSAR methodologies</i>	135
5.6.1	<i>Methods and strategy</i>	135

5.6.2	<i>Application to steroids</i>	137
5.6.3	<i>Application to dopamine D₁ agonists</i>	141
5.6.4	<i>Application to human rhinovirus</i>	143
5.6.5	<i>Pros and cons</i>	146
5.7	<i>Experimental design</i>	146
5.7.1	<i>Factorial design and principal properties</i>	146
5.7.2	<i>Applications of factorial design</i>	148
5.7.3	<i>Combinatorial chemistry and experimental design</i>	152
	<i>Further reading</i>	153
6	Receptors: structure, function and pharmacology	156
	HANS BRÄUNER-OSBORNE	
6.1	<i>Introduction</i>	156
6.1.1	<i>Synaptic processes and mechanisms</i>	158
6.2	<i>Receptor structure and function</i>	159
6.2.1	<i>G-protein coupled receptors</i>	160
6.2.2	<i>Ligand-gated ion channel receptors</i>	162
6.2.3	<i>Tyrosine kinase receptors</i>	164
6.2.4	<i>Nuclear receptors</i>	166
6.3	<i>Receptor pharmacology</i>	168
6.3.1	<i>Recombinant vs. in situ assays</i>	168
6.3.2	<i>Binding vs. functional assays</i>	168
6.3.3	<i>Partial and full agonists</i>	169
6.3.4	<i>Antagonists</i>	170
6.3.5	<i>Allosteric modulators</i>	171
	<i>Further reading</i>	172
7	Ion channels: structure, function and pharmacology	173
	DAVID J. TRIGGLE	
7.1	<i>Introduction</i>	173
7.1.1	<i>Ion channels and cellular function</i>	173
7.1.2	<i>Ion channels as membrane effectors</i>	173
7.1.3	<i>Ion channels and ion distribution</i>	174
7.1.4	<i>Activation and inactivation of ion channels</i>	177
7.2	<i>Structure and function of ion channels</i>	178
7.2.1	<i>Ion channels as efficient and regulated species</i>	178
7.2.2	<i>The structure of ion channels</i>	179
7.2.3	<i>Families of ion channels</i>	180
7.2.4	<i>Structure-function correlations</i>	182
7.3	<i>The classification of ion channels</i>	183
7.3.1	<i>Criteria for ion channel classification</i>	183
7.3.2	<i>Ion channel classification by electrophysiologic criteria</i>	185
7.3.3	<i>Ion channel classification by drug action</i>	185
7.4	<i>Ion channels as pharmacological receptors</i>	188
7.4.1	<i>Receptor properties of ion channels</i>	188
7.4.2	<i>State-dependent interactions of ion channels</i>	188

7.4.3 <i>Structure-activity relationships and state-dependent interactions</i>	191
7.5 <i>Drugs acting at specific ion channels</i>	193
7.5.1 <i>Multiple sites for drug action</i>	193
7.5.2 <i>Drugs acting at Na⁺ channels</i>	193
7.5.3 <i>Drugs acting at Ca²⁺ channels</i>	196
7.5.4 <i>Drugs acting at K⁺ channels</i>	200
7.6 <i>Ion channels and diseases</i>	201
7.7 <i>Ion channels as lethal species</i>	203
7.8 <i>Future developments</i>	203
<i>Further reading</i>	203
8 Radiotracers: synthesis and use in imaging	205
CHRISTER HALLDIN AND THOMAS HÖGBERG	
8.1 <i>Introduction</i>	205
8.2 <i>Nuclear chemistry</i>	206
8.3 <i>Long-lived radionuclides</i>	207
8.3.1 <i>¹⁴C-labeled compounds</i>	208
8.3.2 <i>³H-labeled compounds</i>	209
8.3.3 <i>¹²⁵I-labeled compounds</i>	211
8.4 <i>Short-lived radionuclides</i>	213
8.4.1 <i>¹²³I- and ^{99m}Tc-labeled compounds</i>	213
8.4.2 <i>⁷⁶Br-labeled compounds</i>	215
8.4.3 <i>¹⁸F-labeled compounds</i>	215
8.5 <i>Ultrashort-lived radionuclides</i>	217
8.5.1 <i>¹¹C-labeled compounds</i>	217
8.5.2 <i>¹³N-labeled compounds</i>	222
8.5.3 <i>¹⁵O-labeled compounds</i>	222
8.6 <i>Imaging techniques</i>	223
8.6.1 <i>Autoradiography</i>	223
8.6.2 <i>SPECT</i>	223
8.6.3 <i>PET</i>	224
<i>Further reading</i>	230
9 Excitatory and inhibitory amino acid receptor ligands	232
ULF MADSEN AND BENTE FRØLUND	
9.1 <i>Therapeutic prospects for excitatory and inhibitory amino acids</i>	232
9.1.1 <i>Neurodegenerative diseases</i>	232
9.1.2 <i>CNS ischemia</i>	233
9.1.3 <i>Alzheimer's disease</i>	233
9.1.4 <i>Other neurologic disorders</i>	234
9.2 <i>GABA: inhibitory neurotransmitter</i>	235
9.2.1 <i>Therapeutic targets</i>	235
9.2.2 <i>The GABA molecule</i>	236

9.2.3	<i>GABA biosynthesis and metabolism</i>	238
9.2.4	<i>GABA uptake</i>	241
9.2.5	<i>GABA receptors</i>	244
9.3	<i>Glutamic acid: excitatory neurotransmitter and excitotoxin</i>	253
9.3.1	<i>Classification of and ligands for Glu receptors</i>	254
9.3.2	<i>Ibotenic acid: a naturally occurring excitotoxin and lead structure</i>	263
9.4	<i>Future developments</i>	270
	<i>Further reading</i>	271
10	Acetylcholine and histamine receptors and receptor ligands: medicinal chemistry and therapeutic aspects	272
	POVL KROGSGAARD-LARSEN AND KARLA FRYDENVANG	
10.1	<i>Alzheimer's disease</i>	272
10.2	<i>Cholinergic synaptic mechanisms as therapeutic targets</i>	274
10.2.1	<i>Muscarinic and nicotinic acetylcholine receptors and receptor ligands</i>	276
10.2.2	<i>Muscarinic antagonists as pharmacological tools and therapeutic agents</i>	279
10.2.3	<i>Muscarinic agonists and partial agonists: bioisosteric design</i>	282
10.2.4	<i>Muscarinic agonists and partial agonists: synthetic and structural aspects</i>	285
10.2.5	<i>Nicotinic agonists and partial agonists: bioisosteric design</i>	288
10.2.6	<i>Nicotinic agonists: synthetic aspects</i>	289
10.2.7	<i>Acetylcholinesterase inhibitors</i>	290
10.3	<i>Histamine receptors</i>	292
10.3.1	<i>Protolytic properties of histamine and histamine analogs</i>	294
10.3.2	<i>H₂ and H₃ receptor antagonists: design and therapeutic aspects</i>	294
	<i>Further reading</i>	297
11	Dopamine and serotonin receptor and transporter ligands	299
	KLAUS P. BØGESØ AND BENNY BANG-ANDERSEN	
11.1	<i>Receptors and transporters for dopamine and serotonin</i>	299
11.2	<i>Dopamine and serotonin receptor ligands</i>	300
11.2.1	<i>Molecular biology and structure of receptors for dopamine and serotonin</i>	300
11.2.2	<i>Antipsychotic drugs</i>	302
11.3	<i>Dopamine and serotonin transporter ligands</i>	312
11.3.1	<i>Molecular biology and structure of transporters for biogenic amines</i>	312

11.3.2 Antidepressant drugs	314
11.3.3 Dopamine uptake inhibitors	323
Further reading	326
12 Enzymes and enzyme inhibitors	328
ROBERT A. COPELAND AND PAUL S. ANDERSON	
12.1 Introduction	328
12.2 Chemical mechanisms of enzyme catalysis	329
12.2.1 Transition-state theory in enzyme catalysis	330
12.2.2 Active site structure stabilizes the transition state	335
12.2.3 Strategies for transition-state stabilization	336
12.3 Reversible enzyme inhibitors	342
12.3.1 Competitive inhibition	342
12.3.2 Non-competitive inhibition	350
12.3.3 Uncompetitive inhibition	354
12.4 Other types of inhibitors	356
12.4.1 Slow, tight-binding inhibitors	356
12.4.2 Covalent enzyme modifiers	358
12.4.3 Mechanism-based enzyme inhibitors	360
12.5 Summary	361
Further reading	362
13 Metals in medicine: inorganic medicinal chemistry	364
OLE FARVER	
13.1 Introduction	364
13.1.1 Essential and non-essential elements	365
13.1.2 History	366
13.2 Classification of inorganic pharmaceuticals	367
13.3 The human body and bioinorganic chemistry	368
13.4 Co-ordination chemistry	371
13.4.1 Chelate effect	371
13.4.2 Hard and soft acids and bases (HSAB principle)	373
13.4.3 Kinetics: inert and labile complexes	374
13.4.4 Redox reactions	377
13.4.5 The trans-effect	378
13.4.6 Plasma mobilization index	380
13.5 Chelate therapy	382
13.5.1 Synergistic chelate therapy	382
13.6 Selected chelates	383
13.6.1 BAL	383
13.6.2 D-penicillamine	383
13.6.3 EDTA	383
13.6.4 Desferrioxamine	385
13.7 Drug-metal ion interaction	385
13.7.1 Undesirable interactions	386
13.7.2 Beneficial interactions	386

13.8 Inorganic chemistry and pharmaceuticals	386
13.8.1 Alkali metals	387
13.8.2 Alkaline earth metals	389
13.8.3 The chromium group	391
13.8.4 Iron and cobalt	392
13.8.5 Platinum and ruthenium	398
13.8.6 Copper, silver, and gold	399
13.8.7 Zinc, cadmium, and mercury	404
13.8.8 Antimony and bismuth	407
13.9 Concluding remarks	408
Further reading	409
 14 Design and application of prodrugs	 410
CLAUS S. LARSEN AND JESPER ØSTERGAARD	
14.1 The prodrug concept	410
14.1.1 Definition	410
14.1.2 Barriers to drug action	411
14.1.3 Prodrug design in an industrial setting	412
14.2 Choice and function of the pro-moiety	413
14.2.1 Cleavability of the prodrug bond	414
14.2.2 Modification of physicochemical properties	417
14.2.3 Macromolecular transport vectors	423
14.3 Bioreversible derivatives for various functional groups	426
14.3.1 Esters as prodrugs for compounds containing carboxyl or hydroxy groups	428
14.3.2 Prodrugs for amides, imides and other NH-acidic compounds	430
14.3.3 Prodrugs for amines	435
14.3.4 Prodrugs for compounds containing carbonyl groups	437
14.3.5 Drug activation from intramolecular cyclization reactions	438
14.3.6 Cyclic prodrugs involving two functional groups of the drug	442
14.4 Applications of the prodrug approach	444
14.4.1 Biomembrane passage and bioavailability	444
14.4.2 Site-specific drug delivery	451
14.4.3 Improvement of drug formulation	454
Further reading	458
 15 Peptides and peptidomimetics	 459
KRISTINA LUTTMAN AND ULI HACKSELL	
15.1 Introduction	459
15.1.1 Peptide structure	459
15.1.2 Solid phase peptide synthesis	460

15.1.3	Biosynthesis of peptides	461
15.1.4	Peptide-G-protein coupled receptor interactions	463
15.2	Strategies for peptidomimetic drug discovery	465
15.2.1	Design of peptidomimetics	466
15.2.2	Discovery of peptidomimetics using receptor/enzyme-based screening	473
	Further reading	481
16	Classical antiviral agents and design of new antiviral agents	486
	PIET HERDEWIJN AND ERIK DE CLERCQ	
16.1	Classical antiviral agents	486
16.1.1	Introduction	486
16.1.2	Base-modified pyrimidine nucleosides as antiherpes agents	488
16.1.3	Sugar-modified purine nucleosides	491
16.1.4	Ribavirin	493
16.1.5	Compounds which inhibit the replication of the human immunodeficiency virus (HIV)	494
16.2	Design of new antiviral agents	500
16.2.1	Nucleoside prodrugs	500
16.2.2	Analogs of 5'-monophosphates and nucleotide prodrugs	501
16.2.3	Nucleosides with the non-natural L-configuration	504
16.2.4	Non-nucleoside antivirals outside the anti-HIV field	504
16.2.5	New developments in the anti-HIV-field	507
	Further reading	510
17	Anticancer agents	511
	INGRID KJØLLER LARSEN AND JETTE SANDHOLM KASTRUP	
17.1	DNA as target for anticancer drugs	511
17.1.1	Drugs interacting directly with DNA	512
17.1.2	Drugs interfering with DNA synthesis	537
17.2	Mitotic apparatus as target for drugs	550
17.2.1	Drugs interfering with the Vinca alkaloid binding site of tubulin	550
17.2.2	Drugs interfering with the colchicine binding site of tubulin	553
17.2.3	Drugs stabilizing the assembly of tubulin into microtubules	554
	Further reading	556
	Index	559